[go: up one dir, main page]

MXPA06013039A - El tratamiento de enfermedad respiratoria. - Google Patents

El tratamiento de enfermedad respiratoria.

Info

Publication number
MXPA06013039A
MXPA06013039A MXPA06013039A MXPA06013039A MXPA06013039A MX PA06013039 A MXPA06013039 A MX PA06013039A MX PA06013039 A MXPA06013039 A MX PA06013039A MX PA06013039 A MXPA06013039 A MX PA06013039A MX PA06013039 A MXPA06013039 A MX PA06013039A
Authority
MX
Mexico
Prior art keywords
treatment
respiratory disease
glycopyrrolate
bronchospasm
analogue
Prior art date
Application number
MXPA06013039A
Other languages
English (en)
Inventor
Robin Mark Bannister
Susan Snape
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of MXPA06013039A publication Critical patent/MXPA06013039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El glicopirrolato o un analogo del mismo es util para el tratamiento del broncoespasmo o como una medicacion de rescate.
MXPA06013039A 2004-05-10 2005-05-10 El tratamiento de enfermedad respiratoria. MXPA06013039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410398.2A GB0410398D0 (en) 2004-05-10 2004-05-10 The treatment of respiratory disease
PCT/GB2005/001776 WO2005107872A2 (en) 2004-05-10 2005-05-10 Treating respiratory diseases with gycopyrrolate and analogues

Publications (1)

Publication Number Publication Date
MXPA06013039A true MXPA06013039A (es) 2007-06-19

Family

ID=32526759

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013039A MXPA06013039A (es) 2004-05-10 2005-05-10 El tratamiento de enfermedad respiratoria.

Country Status (14)

Country Link
US (1) US20080020048A1 (es)
EP (1) EP1750806A2 (es)
JP (1) JP2007536361A (es)
CN (1) CN1950127A (es)
AU (1) AU2005240404B2 (es)
BR (1) BRPI0510947A (es)
CA (1) CA2566339A1 (es)
GB (1) GB0410398D0 (es)
IL (1) IL178815A (es)
MX (1) MXPA06013039A (es)
NO (1) NO20065535L (es)
NZ (1) NZ550911A (es)
WO (1) WO2005107872A2 (es)
ZA (1) ZA200609967B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
AU2013205983A1 (en) * 2008-02-26 2013-06-13 Sunovion Respiratory Development Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
JP6013450B2 (ja) * 2012-03-14 2016-10-25 株式会社Ｌｔｔバイオファーマ 慢性閉塞性肺疾患改善剤
WO2014062143A2 (en) * 2012-10-19 2014-04-24 Mahmut Bilgic Anticholinergic agent combinations
WO2014077787A1 (en) * 2012-11-16 2014-05-22 Mahmut Bilgic Combinations including abeta2 agonist and glycopyrrolate
KR20150100902A (ko) * 2012-12-27 2015-09-02 마이크로도스 테라퓨특스, 인코포레이티드 옥시부티닌의 투여를 위한 방법 및 조성물
EP3191081B1 (en) * 2014-09-09 2020-03-25 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
US9968125B2 (en) 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
US9585835B1 (en) 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US20170071248A1 (en) 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease

Also Published As

Publication number Publication date
WO2005107872A2 (en) 2005-11-17
GB0410398D0 (en) 2004-06-16
ZA200609967B (en) 2008-06-25
CN1950127A (zh) 2007-04-18
JP2007536361A (ja) 2007-12-13
EP1750806A2 (en) 2007-02-14
AU2005240404B2 (en) 2009-04-23
NO20065535L (no) 2006-12-08
IL178815A0 (en) 2007-05-15
CA2566339A1 (en) 2005-11-17
WO2005107872A3 (en) 2006-03-16
NZ550911A (en) 2010-10-29
US20080020048A1 (en) 2008-01-24
IL178815A (en) 2011-10-31
AU2005240404A1 (en) 2005-11-17
BRPI0510947A (pt) 2007-11-20

Similar Documents

Publication Publication Date Title
MXPA06013039A (es) El tratamiento de enfermedad respiratoria.
UY28473A1 (es) Nuevos compuestos
UY29633A1 (es) Derivados de oxindol
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CR8831A (es) Compuestos y metodos para el tratamiento de dislipidemia
ATE495745T1 (de) 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotonin- aufnahme, 5-ht3- und 5-ht1a-aktivität zur behandlung von schmerzen oder restsymptomen bei depressionen im zusammenhang mt schlaf und kognition
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
UY30835A1 (es) 8-alquinilxantinas y derivados
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
UY31383A1 (es) N-aroil-n??-(6-(opcionalmente sustituido) alquilsulfonibenzotiazol-2-il)ureas
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
UY30675A1 (es) Metodos para el tratamiento de la depresion
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
SV2006002290A (es) Nonadepsipeptidos acilados ii ref. bhc041327-sv
AR064219A1 (es) Cuerpo moldeado que contiene titanio
CR10038A (es) Analogo de la diazonamida a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal